| |
 |
|
|
|
News
Media Center
Sword Diagnostics Announces Availability
of Proprietary Detection Technology for Ultrasensitive Immunoassays
Chicago, IL - Jan 14, 2010 – Sword
Diagnostics announced today the launch of its proprietary Raman
detection system for ultrasensitive immunoassays. The system provides
researchers with greater sensitivity which enables more accurate
testing of low abundance markers. These increases in performance
could aid researchers in basic and clinical science research, drug
discovery, and clinical diagnostics development.
“We find the resolution at low concentrations to be an exciting
benefit in our ovarian cancer and infertility research,” said
Professor Judith Luborsky, Ph.D, Associate Dean for Research, College
of Health Sciences, Director, Laboratory for Ovarian Cancer Research
and Director, Rush Proteomics & Biomarkers Core Research Facility
at Rush University Medical Center. “The technology was easily
integrated into existing tests with minimal optimization and provided
excellent improvements. In fact, we have included Sword technology
in several grants we are currently applying for.”
“We are pleased with the positive reception our technology
has received from the market. The key opinion leaders have found
it particularly useful for highly sensitive ELISAs,” said
Dave Dingott, founder and CEO of Sword Diagnostics. “The
Raman plate reader allows current ELISA users to continue using
their 96-well format, making conversion to our technology extremely
simple and cost effective.”
About Sword Diagnostics
Sword Diagnostic’s mission is to improve existing immunoassays
by providing additional sensitivity to currently available antibody-based
test as well as allowing researchers to monitor new markers that
are not readily detectable with current technology. This may lead
to earlier and more accurate diagnosis of diseases such as cancer,
cardiovascular disorders, and Alzheimer’s disease. Better
diagnosis results in simpler treatments with more positive outcomes
for patients and less costs.
Sword markets its technology for biomarker measurement for pharmaceutical
drug discovery and academic life science researchers and will partner
to develop clinical diagnostics assays. The technical solution
is an immunoassay detection system that uses Raman spectroscopy
and a proprietary chemistry. The system extends the sensitivity
over current detection technologies while being easily incorporated
into assays that use a peroxidase-based detection system.
Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com
|
|
|
|
|
|
|
|
|
|
|
| |
U.S. Patent Office Issues Sword Diagnostics
Patent for Highly Sensitive Immunodetection Technology
Chicago, IL - Dec 14, 2009 – Sword
Diagnostics, Inc. is pleased to announce that the United States
Patent Office (USPTO) has issued patent number 7,599,057 titled “ Method
and Apparatus for Detection of Biological Organisms using Raman
Scattering” to the company. The patent covers the core technology
which focuses on improved sensitivity and specificity.
“The issuance of this patent supports the underlying strategy as we move
forward with our continued development and commercialization” said Dave
Dingott, CEO and President of Sword Diagnostics. “The feedback from our
immunoassay customers validates the high degree of need in the market for a technology
that delivers improved sensitivity without compromising in cost or complexity
of the test.”
About Sword Diagnostics
Sword Diagnostic’s mission is to improve existing medical diagnostic tests
by providing additional sensitivity to each currently available antibody-based
test as well as allowing clinicians to monitor new markers that are not detectable
with current technology. This will allow earlier and more accurate diagnosis
of diseases such as cancer, cardiovascular disorders, and Alzheimer’s disease.
Better diagnosis results in simpler treatments with more positive outcomes for
patients and less costs.
Sword markets its technology for biomarker measurement for pharmaceutical drug
discovery and academic life science researchers and will partner to develop clinical
diagnostics assays.
The technical solution is an immunoassay detection system that uses Raman spectroscopy
and a proprietary chemistry. The system extends the sensitivity over current
detection technologies while being easily incorporated into assays that use a
peroxidase-based detection system.
Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com
|
|
|
|
|
|
|
|
